Malignant Melanoma | Unmet Need | US/EU | 2016
Since 2011, several novel first-line unresectable or metastatic malignant melanoma therapies have gained approval in the U.S. and in Europe. These agents, namely immunotherapies and BRAF and MEK inhibitors, have revolutionized the treatment landscape of malignant melanoma, considerably improving patients’ survival. Despite the remarkable improvement in survival, the prevailing unmet needs in first-line unresectable or metastatic malignant melanoma therapies still consolidate around the improvements in efficacy, creating a significant clinical and commercial opportunity for drug developers to exploit with new therapies which can extend patients lives.
Related Market Assessment Reports
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Drug treatment of heart failure with reduced ejection fraction (HFrEF) is well established, backed by a wealth of supporting evidence from clinical trials. RAAS inhibitors and beta blockers are the…
Report
Primary Biliary Cholangitis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease, characterized by inflammation and progressive damage leading to destruction of interlobular bile ducts, followed by cholestasis…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
